Please ensure Javascript is enabled for purposes of website accessibility


Big things are happening at Ogier. Change is embedded in everything we do. It is redefining our talent, our ways of working, our platforms of delivery, our culture.



We have the expertise to handle the most demanding transactions. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies means we add real value to clients’ businesses.

View all services

Business Services Team

View all Business Services Team


Our sector approach relies on smart collaboration between teams who have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients to see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier Guernsey advises Stanley Capital on new investment structure and acquisition of Noden Pharma


01 October 2020


2 min read

Ogier's Guernsey team has assisted Stanley Capital with the establishment of a Guernsey investment structure and the acquisition of Noden Pharma DAC and Noden Pharma USA (Noden), a leading speciality pharmaceutical company.

The multi-disciplinary Ogier team worked with Stanley Capital, lead counsel Willkie Farr & Gallagher (London) LLP and alterDomus. The team was led by partner Bryon Rees and senior associate Michelle Watson Bunn, with support from partners Tim Clipstone and Bryan De Verneuil-Smith, senior associate Charlotte Brown and associate Henry Simpson.

Bryon Rees commented: "We are delighted to have supported Stanley Capital and its advisors on this new investment structure and the initial acquisition, creating a solid base for future growth into a leading pharma platform."

Noden is focused on providing unique, complex to manufacture prescription medicines for cardiovascular patients who are intolerant to mainstream treatments. It is the first acquisition and a core platform for implementing a strategy to consolidate the mature product speciality pharma marketplace. Stanley Capital, working alongside Noden's management team, will pursue a value investment philosophy, targeting the acquisition of multiple drug portfolios to create a differentiated and highly cash generative portfolio of attractive medicines with established operational, technical, or patent-led barriers to entry.

Simon Cottle, partner at Stanley Capital, said: “The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden’s excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions.”

Stanley Capital is a private equity partnership pursuing repeatable relative value and thematic investment strategies in technology, healthcare, and sustainability, targeting businesses with enterprise values of $250mn to $2.5bn.

No Content Set